Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

New GLP analogue launched

Liraglutide (Victoza®) has been launched for the treatment of patients with type 2 diabetes. This new drug is a glucagon-like peptide (GLP-1) analogue and is in the same class as exenatide (Byetta®).

There are slight differences between the two products in terms of the product licence. Exenatide is licensed for combination use with metformin and/or a sulphonylurea in patient not achieving adequate glycaemic control. Liraglutide is licensed in these same combinations and also in combination with metformin and a glitazone.

Exenatide has been considered in the most recent NICE Diabetes guidance but specific advice from NICE for liraglutide is not due until June 2010.

Action: Clinicians should be aware of this new drug, the licensed indications and status of the current NICE guidance.

Share 'New GLP analogue launched' on Email Share 'New GLP analogue launched' on Delicious Share 'New GLP analogue launched' on Digg Share 'New GLP analogue launched' on Facebook Share 'New GLP analogue launched' on Google+ Share 'New GLP analogue launched' on reddit Share 'New GLP analogue launched' on StumbleUpon Share 'New GLP analogue launched' on Twitter

atomic-wealth

No Comments to “New GLP analogue launched”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,523 spam comments.

atomic-wealth
fond-illness
summer